--- title: "Cardiovascular & Respiratory Medicines" ocid: "ocds-r6ebe6-0000485336" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000485336" markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000485336.md" json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000485336.json" source: "Public Contracts Scotland" current_stage: "Award" buyer: "THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (\"THE AUTHORITY\")" published: "2017-07-14" --- # Cardiovascular & Respiratory Medicines Buyer: THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("THE AUTHORITY") Current stage: Award OCID: ocds-r6ebe6-0000485336 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000485336) [Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000485336.json) ## Summary The procurement process involves the Common Services Agency (NHS National Services Scotland) seeking suppliers for a framework agreement titled "Cardiovascular & Respiratory Medicines." This procurement falls under the goods category within the health industry and is located in Edinburgh, Scotland. It is currently in the Tender stage, with the closing date for submission set for 24 April 2017. The procurement method employed is an open procedure, and the total estimated value of the contract is approximately £22,123,563, covering a period of 24 months with a possible extension of 12 months. This tender presents significant opportunities for pharmaceutical and healthcare companies, especially those specialising in generic medicines for cardiovascular and respiratory conditions. Businesses that can demonstrate adherence to regulatory requirements, such as possessing a valid UK or EMA Marketing Authorisation and ISO certification, will be well-positioned to compete. With the potential to supply various medicines, including injectables and inhalers, suppliers should consider bidding for specific Lots based on their product capabilities to secure contracts with the NHS. ## Notice Medicines included in this framework agreement are generic medicines listed in the British National Formulary (BNF) used to treat cardiovascular and respiratory conditions. The Goods have been split into thirteen (13) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice. ### Lot Information Epinephrine (Adrenaline) Pre-filled Syringes Supply of Epinephrine (Adrenaline) Injections to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Epinephrine (Adrenaline) Auto Injector Devices Supply of Epinephrine (Adrenaline) Auto Injector Devices to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Fondaparinux Pre-filled Syringes Supply of Fondaparinux Pre-filled Syringes to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. All Other Cardiovascular & Respiratory Medicines Supply of all other Cardiovascular & Respiratory Medicines to NHS Scotland in a range of presentations. The Authority intended to award each line within this lot to a single supplier. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire Urokinase Injections Supply of Urokinase Injections to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire Diltiazem Hydrochloride Modified Release Capsules and Tablets Supply of Diltiazem Hydrochloride Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Isosorbide Mononitrate Modified Release Capsules and Tablets Supply of Isosorbide Mononitrate Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Verapamil Hydrochloride Modified Release Capsules and Tablets Supply of Verapamil Hydrochloride Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Nifedipine Modified Release Capsules and Tablets Supply of Nifedipine Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Theophylline Modified Release Capsules and Tablets Supply of Theophylline Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Branded and Branded Generic Inhalers Supply of Branded and Branded Generic Inhalers to NHS Scotland in a range of presentations. The Authority intended to award each product line as a multi-supplier unranked framework agreement on a line by line basis to an envisaged maximum of 6 Suppliers. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Epoprostenol powder and solvent (pH10.5) for solution for infusion vials Supply of Epoprostenol 500mcg and 1.5mg powder and solvent (pH10.5) for solution for infusion vials to NHS Scotland. The Authority intended to award a multi-supplier unranked framework agreement for the Lot to an envisaged maximum of 6 Suppliers.. Access to contract pricing required by the designated Homecare company for supply to patients receiving treatment for Pulmonary Arterial Hypertension via the Homecare delivery contract. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. Epoprostenol powder and solvent (pH12) for solution for infusion vials Supply of Epoprostenol 500mcg and 1.5mg powder and solvent (pH12) for solution for infusion vials to NHS Scotland. The Authority intended to award a multi-supplier unranked framework agreement for the Lot to an envisaged maximum of 6 Suppliers.. Access to contract pricing required by the designated Homecare company for supply to patients receiving treatment for Pulmonary Arterial Hypertension via the Homecare delivery contract. Renewal: Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire. ## Key Details | Field | Value | | --- | --- | | Publication source | Public Contracts Scotland | | Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL289619 | | Notice type | OJEU - F3 - Contract Award Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Not specified | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 14 Jul 2017 | | Submission deadline | 24 Apr 2017 | | Future notice date | Not specified | | Award date | 4 Jul 2017 | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £22,123,563 | | Lots value | £22,123,563 | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Complete | | Awards status | Unsuccessful | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("THE AUTHORITY") | | Locality | EDINBURGH | | Post town | Edinburgh | | Postcode | EH12 9EB | | Country | Scotland | | ITL 1 | TLM Scotland | | ITL 2 | TLM1 East Central Scotland | | ITL 3 | TLM13 City of Edinburgh | | Local authority | City of Edinburgh | | Electoral ward | Drum Brae/Gyle | | Westminster constituency | Edinburgh South West | | Delivery location | TLM Scotland | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 14 Jul 2017 at 00:00 - Award - OJEU - F3 - Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL289619 - 21 Mar 2017 at 00:00 - Tender - OJEU - F2 - Contract Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR277762 ## Documents - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR277762 Cardiovascular & Respiratory Medicines - Medicines included in this framework agreement are generic medicines listed in the British National Formulary (BNF) used to treat cardiovascular and respiratory conditions. The Goods have been split into thirteen (13) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice. - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL289619 Cardiovascular & Respiratory Medicines - Medicines included in this framework agreement are generic medicines listed in the British National Formulary (BNF) used to treat cardiovascular and respiratory conditions. The Goods have been split into thirteen (13) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice. ## Notice URLs - http:// - http://www.nhsscotlandprocurement.scot.nhs.uk/ - http://www.publiccontractsscotland.gov.uk/Default.aspx - https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000485336 - https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000485336. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000485336.json.